ImmuPharma plc (LON:IMM – Get Free Report)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 4.45 and traded as high as GBX 4.89. ImmuPharma shares last traded at GBX 4.30, with a volume of 1,755,733 shares changing hands.
ImmuPharma Stock Performance
The firm has a market cap of £26.83 million, a price-to-earnings ratio of -11.62 and a beta of 3.00. The firm’s 50 day moving average is GBX 4.45 and its 200-day moving average is GBX 5.73.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Wednesday, May 27th. The company reported GBX (0.37) EPS for the quarter. ImmuPharma had a negative return on equity of 1,397.44% and a net margin of 3,519.56%. As a group, research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
